CD274 and female reproductive organ cancer: ICIs, including anti programmed cell death protein-1 (anti-PD-1)/anti-programmed death-ligand 1 (anti-PD-L1) antibodies, have attracted the greatest interest in clinical trials given the molecular basis of gynecologic cancers.